The AI Content Playbook for Pharma: Turning Trending Questions into GEO Strategy

AI models are being asked 46 competitive questions about a single drug. Is your content answering them?

Across nine articles in this series, we have diagnosed the problem from every angle. AI models ignore your brand name. Your website pays a reliability tax. Citations cluster around just five sources. Adverse events slip through the pharmacovigilance blind spot. Legacy drugs dominate share of voice. Sentiment does not predict performance. The benchmarks are clear, the gaps are documented, and the competitive landscape is mapped.

Now it is time to build.

This is the implementation playbook. No more diagnostics. No more benchmarks. This article gives pharma content teams the step-by-step framework for creating content that AI models actually surface, cite, and use to answer the questions patients, physicians, and payers are asking right now.

The framework is built on real trending question data from the PharmaGEO platform, validated GEO and AEO best practices, and technical implementation guidance specific to pharmaceutical websites.

Key Takeaway: This playbook synthesizes data from 23 pharmaceutical brands and three AI models into an eight-step content framework. Each step maps directly to measurable GEO performance improvements identified in our platform analysis.

Data source: PharmaGEO platform analysis across OpenAI, Gemini, and Perplexity (2025)

---

The Question Map: What AI Models Are Being Asked About Your Drug

Before building content, you need to know exactly what questions AI models are fielding about your product. Our platform analysis reveals that patient and professional queries cluster into six predictable categories, consistent across therapeutic areas and brands.

The Trending Questions Hierarchy

This hierarchy is not hypothetical. It reflects the actual distribution of pharma trending questions AI models receive, ranked by frequency across our dataset.

The pattern holds across categories. Whether analyzing an immunologic, an oncology therapy, or a consumer health product, the same six question types dominate. The variation is in specificity (which side effects, which competitors, which administration method), not in structure.

Key Takeaway: Every pharmaceutical brand faces the same six question archetypes in AI search. Content strategies that systematically address all six outperform those that cover only one or two. Map your product's specific variations of each archetype before creating a single piece of content.

This is foundational to any pharma content strategy AI optimization effort. If your content does not address these six question types with clear, structured, citation-ready answers, AI models will source answers from somewhere else --- and as we documented in our five-source analysis, that "somewhere else" is rarely your owned domain.

---

The Competitive Battleground: Why Comparison Questions Dominate

The most striking finding in our trending question analysis is not the patient questions. It is the competitive questions.

Entyvio: A Case Study in Competitive Query Volume

Forty-six competitive trending questions for a single brand. These are not abstract, generic queries. They are specific, high-intent comparison searches:

- Skyrizi vs Entyvio

- Tremfya vs Entyvio

- Rinvoq vs Entyvio

Each query represents a patient or physician at a decision point --- actively weighing one treatment against another. These are the highest-intent queries in pharmaceutical AI search, and they outnumber patient and professional questions combined by more than two to one.

Why This Matters for Content Strategy

Most pharmaceutical brand websites are built around a single product narrative. They explain the drug, its mechanism, its efficacy, and its safety profile. What they almost never do is explicitly address how the product compares to specific competitors.

The reasons are understandable. Regulatory caution. Legal review bottlenecks. Fair balance requirements. But the result is a content vacuum that AI models fill with third-party sources --- clinical review sites, medical education platforms, and independent creators whose content may not reflect the most current or complete evidence.

The 46-to-11 ratio is not unique to Entyvio. Across our dataset, competitive questions consistently represent the largest share of trending queries for established brands in crowded therapeutic areas. As we showed in our AI model comparison analysis, each model handles these comparison queries differently, but all three surface them frequently.

Key Takeaway: Competitive comparison queries outnumber patient and professional questions by as much as 4:1. Brands that do not create compliant, evidence-based comparative content cede the narrative to third-party sources that AI models will cite instead.

This is the battleground. And it connects directly to the share of voice dynamics we analyzed earlier in this series --- legacy drugs with deeper evidence bases often win these comparisons simply because more comparative data exists for them.

---

The "2025 Guidelines" Effect: Time-Sensitivity in AI Queries

A pattern emerged in our trending question data that pharma teams cannot afford to ignore: patients and physicians are asking AI models about current-year treatment guidelines by name.

Real Trending Questions Referencing Guidelines

Queries like "Why do the 2025 AGA guidelines recommend Skyrizi over Entyvio?" are appearing in our platform analysis. This is not a generic question about treatment options. It is a specific, time-stamped query about a named guideline update, a named recommendation, and a named competitive dynamic.

This creates three problems for pharma content teams:

1. Static brand websites cannot keep pace. Most pharmaceutical websites are updated on quarterly or semi-annual cycles. Treatment guidelines are updated on their own schedule, and AI models begin fielding questions about those updates within days.

2. AI models may not have current information. As we documented in our benchmarking analysis, AI models have training data cutoffs. When users ask about 2025 guidelines, the model may be working with outdated information or hedging its response with caveats about recency.

3. The brand that answers first wins the citation. When a guideline update shifts the competitive landscape, the first credible source to publish a clear, structured summary of what changed and why becomes the source AI models are most likely to cite. This is the pharmaceutical AI search content advantage that few brands are exploiting.

Key Takeaway: Treatment guideline updates create time-sensitive content windows. Brands that publish structured, guideline-responsive content within days of major updates gain a disproportionate citation advantage in AI search. Build a guideline-response workflow into your content operations.

The "2025 guidelines" effect also intersects with the reliability dynamics we analyzed earlier. AI models evaluate source reliability partly on whether the information is current. A brand website referencing 2023 guidelines when 2025 guidelines exist signals to the model that the source may be outdated --- reducing both reliability scores and citation likelihood.

---

The YouTube Signal: Video Content in AI Overviews

Video content is an increasingly significant factor in AI-generated answers, and the data from our platform analysis reveals patterns that pharma teams should incorporate into their GEO content optimization pharma strategy.

What the Data Shows

Patient experience videos dominate viewership. A single Dupixent pen injection tutorial has accumulated 4.2 million views. Administration walkthroughs, patient testimonials, and "day in my life" treatment videos consistently outperform clinical education content in raw view counts.

But views do not equal AI citations. The correlation between YouTube view count and AEO (Answer Engine Optimization) citation is weak. What drives citation is relevance and authority, not popularity.

Medical education channels carry the highest authority. Content from institutions like Mayo Clinic and Cleveland Clinic is disproportionately cited in AI overviews relative to its view count. Authority signals --- institutional affiliation, medical review processes, consistent publishing cadence --- matter more than virality.

Google AI Overviews by Brand

Our platform tracking shows significant variation in AI Overview appearances:

- Entyvio: 67 AI Overview appearances

- Psoriasis (category): 50 AI Overview appearances

- Beyfortus: 15 AI Overview appearances

These numbers reflect the current state of pharmaceutical AI search content saturation. Brands and categories with deeper content ecosystems generate more AI Overview triggers.

Key Takeaway: Video content matters for AI search, but authority outweighs virality. Pharma brands should prioritize medically reviewed, structured video content over high-production patient stories when optimizing for AEO citations. Partner with medical education institutions where possible.

---

The GEO Content Framework: Eight Steps to AI-Optimized Pharma Content

This is the core of the playbook. Each step builds on the data and analysis from this series, translating insights into specific content actions. This is the pharma GEO playbook distilled into implementation.

Step 1: Map Your Trending Questions

What to do: Use the PharmaGEO platform (or equivalent monitoring tools) to identify every question AI models are being asked about your product. Categorize each question against the six-archetype hierarchy.

How to do it:

- Pull trending questions for your brand across ChatGPT, Gemini, and Perplexity

- Tag each question: patient, professional, or competitive

- Map gaps: which archetypes have no owned content answering them?

- Prioritize competitive questions --- they represent the highest intent and the largest volume

Output: A complete question map with priority rankings and content gap flags.

As we established in our brand recognition analysis, AI models default to generic terminology. Your question map must include both brand-name and INN-based query variations.

---

Step 2: Create Answer-Paragraph Content

What to do: For every high-priority trending question, create a standalone "answer paragraph" --- a concise, self-contained response that AI models can extract and cite directly.

How to do it:

- Write each answer in 40-60 words (the optimal length for AI extraction)

- Lead with the direct answer, then add context

- Include the product name (brand and INN) in the first sentence

- Reference the approved prescribing information as the source

- Use factual, neutral language --- not promotional copy

Example structure:

Question: How does [Product] work?

>

Answer paragraph: [Product] (INN) is a [mechanism class] that works by [mechanism of action]. It is indicated for [approved indications]. According to the prescribing information, [Product] [key differentiating clinical fact]. [Source: FDA-approved prescribing information, [year].]

Why this works: As our reliability analysis showed, AI models prioritize sources that align with FDA/EMA prescribing information. Answer paragraphs built directly from approved labeling score higher on reliability, which is the single strongest predictor of overall GEO performance.

Key Takeaway: Answer paragraphs are the atomic unit of GEO content. Every trending question should have a corresponding 40-60 word answer paragraph on your owned domain, written in neutral language and sourced from approved labeling.

---

Step 3: Implement Structured Data

What to do: Add schema.org structured data markup to every page that contains answer-paragraph content. This is the technical backbone of answer engine optimization pharma content.

Required schema types:

FAQPage Schema --- for pages with question-and-answer content:

```json

{

"@context": "https://schema.org",

"@type": "FAQPage",

"mainEntity": [{

"@type": "Question",

"name": "How does [Product] work?",

"acceptedAnswer": {

"@type": "Answer",

"text": "[Your 40-60 word answer paragraph]"

}

}]

}

```

Drug/Product Schema --- for product information pages:

```json

{

"@context": "https://schema.org",

"@type": "Drug",

"name": "[Brand Name]",

"nonProprietaryName": "[INN]",

"drugClass": "[Drug Class]",

"mechanismOfAction": "[Mechanism]",

"administrationRoute": "[Route]",

"prescribingInfo": "[URL to PI]"

}

```

MedicalWebPage Schema --- for clinical content:

```json

{

"@context": "https://schema.org",

"@type": "MedicalWebPage",

"about": {

"@type": "Drug",

"name": "[Brand Name]"

},

"lastReviewed": "[Date]",

"reviewedBy": {

"@type": "Organization",

"name": "[Medical Review Body]"

}

}

```

Implementation priority: Start with FAQPage schema on your dosing, safety, and mechanism-of-action pages. These are the pages most likely to match trending question queries.

---

Step 4: Build an Evidence Library

What to do: Create a dedicated section of your website that aggregates and links to all relevant clinical evidence --- treatment guidelines, peer-reviewed publications, regulatory documents, and real-world evidence.

How to build it:

- Guideline links: Direct links to current AGA, ACR, NCCN, or relevant specialty society guidelines

- Publication summaries: One-paragraph summaries of pivotal trials with links to PubMed or journal sources

- Regulatory documents: Links to FDA/EMA approval letters, PI updates, and labeling supplements

- Real-world evidence: Links to post-marketing studies and registry data

Why this matters: Our citation analysis showed that AI models concentrate citations on a narrow set of authoritative sources. An evidence library on your owned domain creates a single, linkable destination that consolidates the type of sources AI models already trust. It transforms your website from a marketing asset into a reference asset.

Embed FDA/EMA PI citations sitewide. Every clinical claim on your website should link back to the specific section of the prescribing information that supports it. This is the single most impactful GEO content optimization pharma teams can implement immediately.

Key Takeaway: An evidence library is not a "nice to have." It is the structural foundation that elevates your owned domain from marketing collateral to an AI-citable reference source. Link every clinical claim to its PI source, and aggregate all external evidence in one navigable location.

---

Step 5: Address Competitive Comparisons Explicitly

What to do: Create compliant, evidence-based content that directly addresses the competitive comparison questions dominating your trending query data.

How to do it within regulatory constraints:

- Focus on clinical differentiation rather than superiority claims

- Present data from head-to-head trials where they exist

- Reference guideline positioning (which guidelines recommend what, and in what sequence)

- Use neutral framing: "In [Trial Name], [Product A] demonstrated [outcome] compared to [Product B]'s [outcome]"

- Always include fair balance and safety information for both products

- Have medical, legal, and regulatory (MLR) review processes that can turn around comparison content in days, not months

The content format that works:

- Structured comparison tables (mechanism, administration, efficacy endpoints, safety profile)

- FAQ-format Q&A addressing specific "vs" queries

- Guideline positioning summaries showing where each product sits in treatment algorithms

Why speed matters: As we showed in the [guidelines effect section](#the-2025-guidelines-effect-time-sensitivity-in-ai-queries), guideline updates shift competitive positioning. The first brand to publish a structured, compliant comparison reflecting updated guidelines captures the citation.

This step connects directly to the competitive dynamics analyzed in our share of voice research. Newer brands with thinner evidence bases must be more deliberate about creating comparative content because the default AI response will favor the legacy competitor with deeper published evidence.

---

Step 6: Update for Guideline Changes

What to do: Build a content operations workflow that publishes guideline-responsive content within 48-72 hours of major treatment guideline updates.

The guideline-response workflow:

1. Monitor: Track publication dates for all relevant specialty society guidelines (AGA, ACR, ASCO, NCCN, ESC, etc.)

2. Pre-draft: Before guideline release, prepare templated content for likely scenarios (product moves up in algorithm, product moves down, new competitor added, etc.)

3. Review: Have pre-approved MLR pathways for guideline-response content with expedited review cycles

4. Publish: Within 48-72 hours, publish a structured summary: what changed, what it means for patients, how it affects treatment sequencing

5. Distribute: Ensure the content is indexed and crawlable --- submit to Google Search Console, update your sitemap, and cross-link from relevant product pages

The template structure:

[Year] [Guideline Name] Update: What Changed for [Product]

>

The [year] [society] guidelines for [condition] were published on [date]. Key changes relevant to [Product] include: [bullet points of changes]. [Product] is now positioned as [position in algorithm]. For the complete guideline, see [link to source].

This is pharmaceutical AI search content that few brands produce because it requires cross-functional speed. The ones that do produce it gain disproportionate visibility.

---

Step 7: Create Video Content

What to do: Develop medically reviewed video content optimized for AI Overview citation, not just YouTube viewership.

Priority video types:

1. Mechanism of action explainers (2-3 minutes, animated)

2. Administration/injection tutorials (step-by-step, 3-5 minutes)

3. Physician Q&A format (addressing top trending questions, 5-8 minutes)

4. Guideline update summaries (what changed and why, 3-5 minutes)

AEO optimization for video:

- Include the product name (brand and INN) in the video title, description, and first 30 seconds of narration

- Add structured VideoObject schema to the hosting page

- Provide a full transcript on the page (AI models index text, not video)

- Use chapter markers that match trending question phrasing

- Tag videos with MedicalAudience schema where appropriate

Partner strategy: As the data shows, medical education institution channels (Mayo Clinic, Cleveland Clinic) carry the highest AEO authority. Explore co-creation partnerships or sponsored educational content with these institutions.

Key Takeaway: Video content optimized for AEO citation requires transcripts, structured data, and medical authority signals --- not just high production value. A medically reviewed 3-minute explainer with proper schema markup outperforms a viral patient video in AI citation likelihood.

---

Step 8: Monitor and Iterate

What to do: Establish ongoing GEO performance monitoring and quarterly content iteration cycles.

Monitoring cadence:

- Weekly: Track trending question shifts and new competitive queries

- Monthly: Review AI Overview appearance counts and citation sources

- Quarterly: Full GEO score audit across all three AI models (ChatGPT, Gemini, Perplexity)

Iteration triggers:

- New guideline publication in your therapeutic area

- New competitor launch or approval

- Significant shift in trending question patterns

- GEO score drop below baseline on any model

- New AI model feature (e.g., expanded AI Overviews, new citation formats)

What to measure:

This is where the benchmarking framework we published earlier in this series becomes operational. Your benchmark is not a one-time audit --- it is the baseline against which every content iteration is measured.

---

Technical Implementation Checklist

This section consolidates every technical action from the eight-step framework into a single, auditable checklist. Use this as your implementation tracking document.

On-Page SEO and GEO

- [ ] H1 tags include product name (brand name and INN) on every product page

- [ ] Meta descriptions include indication-specific language (not generic brand messaging)

- [ ] Answer paragraphs (40-60 words) exist for all six question archetypes

- [ ] Cross-links connect efficacy pages, safety pages, and evidence library bidirectionally

- [ ] Explicit indication Q&A content exists on the homepage or primary landing page

- [ ] "Indications and Usage" answer box appears above the fold on the primary product page

Structured Data

- [ ] FAQPage schema implemented on all Q&A and dosing/safety pages

- [ ] Drug schema (schema.org/Drug) implemented on primary product page

- [ ] MedicalWebPage schema implemented on clinical content pages

- [ ] VideoObject schema implemented on all pages with embedded video

- [ ] BreadcrumbList schema implemented sitewide for navigation structure

Evidence Library

- [ ] Dedicated evidence library page exists with defined URL structure

- [ ] FDA/EMA PI citations embedded on every page making clinical claims

- [ ] Guideline links point to current (not outdated) society guidelines

- [ ] Publication summaries include PubMed or DOI links

- [ ] Last reviewed date displayed on every clinical content page

Content Operations

- [ ] Guideline monitoring calendar maintained for all relevant specialty societies

- [ ] Pre-drafted guideline response templates prepared for likely scenarios

- [ ] Expedited MLR review pathway established for guideline-response content

- [ ] Competitive comparison content addresses top 10 "vs" queries

- [ ] Video content pipeline includes mechanism, administration, and guideline updates

Monitoring Infrastructure

- [ ] PharmaGEO platform (or equivalent) configured for weekly trending question pulls

- [ ] AI Overview tracking automated for brand and category terms

- [ ] Quarterly GEO audit scheduled with defined scorecard metrics

- [ ] Cross-model consistency tracked across ChatGPT, Gemini, and Perplexity

Key Takeaway: This checklist is not aspirational. Every item maps to a specific GEO performance driver identified in our 23-brand analysis. Prioritize structured data and evidence library items first --- they deliver the fastest measurable impact.

---

Connecting the Full Series: Where Each Insight Drives Action

This playbook does not exist in isolation. Every step is grounded in the data and analysis published across the previous nine articles in this series. Here is how they connect:

The pharmacovigilance analysis also informs every step: all content must include appropriate safety information, adverse event reporting pathways, and regulatory-compliant fair balance. AI models that surface your content must not create PV compliance gaps.

---

Frequently Asked Questions

How long does it take to see GEO improvements after implementing this playbook?

Structured data changes (schema markup, H1 optimization, meta descriptions) can begin influencing AI model behavior within 4-8 weeks as pages are re-indexed. Evidence library and answer-paragraph content typically shows measurable impact within one quarterly GEO audit cycle. Competitive comparison content and guideline-response workflows deliver the most immediate impact because they address high-intent queries with no existing owned content. The full playbook, implemented end-to-end, should produce measurable GEO score improvements within 90 days.

Can pharma brands legally create competitive comparison content for AI search?

Yes, within regulatory constraints. Comparative content must be based on published clinical evidence, present fair balance, and avoid superiority claims not supported by head-to-head trial data. The key is framing: present objective clinical data from named trials rather than marketing positioning. Treatment guideline references are particularly effective because they represent third-party expert consensus, not brand claims. All competitive content should go through standard MLR review before publication.

Which step in the playbook delivers the highest ROI for pharma content strategy AI optimization?

Step 3 (structured data implementation) and Step 4 (evidence library) consistently deliver the fastest measurable returns because they improve how AI models parse and cite existing content. Many pharmaceutical websites already have relevant clinical information but lack the structured markup and cross-linking that makes it extractable by AI models. Implementing FAQPage and Drug schema on existing pages is often the single highest-impact action because it requires no new content creation --- only technical optimization of what already exists.

How should pharma companies handle the "2025 guidelines" queries when guidelines change frequently?

Build a standing guideline-response workflow with pre-approved content templates and an expedited MLR review track. Monitor publication calendars for all relevant specialty societies. When a guideline update drops, activate the workflow: update your evidence library, publish a structured summary, refresh any comparison content affected by the change, and submit updated pages for re-indexing. The goal is 48-72 hour turnaround from guideline publication to live content. Companies that institutionalize this workflow gain a structural advantage because most competitors require weeks or months to update.

Does this playbook apply differently across AI models like ChatGPT, Gemini, and Perplexity?

The eight steps are universal, but each model weighs signals differently. Perplexity relies most heavily on real-time web citations, making evidence libraries and fresh guideline content especially impactful. Gemini integrates more deeply with Google's search index, so structured data and AI Overview optimization deliver outsized returns. ChatGPT draws more from its training data, making consistent, long-term content publishing the key lever. The monitoring framework in Step 8 tracks performance across all three models precisely because a strategy optimized for only one model will underperform on the others.

How does this playbook account for non-English markets?

The framework applies universally, but implementation must be localized. As our [French market analysis](/blog/french-market-geo-gap-pharma-ai-search) revealed, non-English pharmaceutical content is dramatically underrepresented in AI search --- zero AI Overviews in French versus 67 for Entyvio in English. This gap is both a challenge and an opportunity. Brands that implement this playbook in non-English markets face less competition for AI citations. Prioritize Steps 2 (answer paragraphs), 3 (structured data), and 4 (evidence library) in local languages first, using locally approved prescribing information and regional guidelines as source material.

---

Conclusion: From Diagnosis to Implementation

This series began with a stark finding: AI models use pharmaceutical brand names 0% of the time. Across nine subsequent articles, we quantified the reliability gap, mapped the citation landscape, exposed the pharmacovigilance blind spot, benchmarked 23 brands on GEO Pharma performance, compared AI models, measured share of voice in AI, identified the non-English GEO gap, and debunked the sentiment myth.

The diagnosis is complete. The prescription is this playbook.

The brands that will lead in pharmaceutical AI search are not the ones with the biggest budgets or the most recognizable names. They are the ones that treat AI models as a new information channel with its own rules --- rules that reward reliability over persuasion, structure over storytelling, and evidence over promotion.

Forty-six competitive questions are being asked about a single drug. Guideline updates are triggering time-sensitive queries within days. Patients are watching 4.2-million-view injection tutorials. Physicians are asking AI models to compare treatments side by side.

Your content either answers these questions --- or someone else's does.

Start with Step 1. Map your questions. Build from there.

Final Key Takeaway: AI search in pharma is not a future trend. It is a current reality with measurable competitive consequences. This eight-step playbook transforms trending question data into structured, compliant, citation-ready content. The implementation window is open now. The brands that move first gain compounding advantages that become harder to close with each passing quarter.

Data source: PharmaGEO platform analysis across OpenAI, Gemini, and Perplexity (2025)

---

This is the final article in our series on pharmaceutical AI visibility and Generative Engine Optimization. For the complete analytical foundation behind this playbook, start with Article 1: The 0% Brand Recognition Crisis and read through the full series on the GEO Pharma Research Hub.

Data source: PharmaGEO platform analysis of 23 pharmaceutical brands across OpenAI, Gemini, and Perplexity (2025)